MA38208B1 - Inhibiteurs de bmi-1 pyrimidines inversés substitués - Google Patents

Inhibiteurs de bmi-1 pyrimidines inversés substitués

Info

Publication number
MA38208B1
MA38208B1 MA38208A MA38208A MA38208B1 MA 38208 B1 MA38208 B1 MA 38208B1 MA 38208 A MA38208 A MA 38208A MA 38208 A MA38208 A MA 38208A MA 38208 B1 MA38208 B1 MA 38208B1
Authority
MA
Morocco
Prior art keywords
bmi
inhibitors
substituted
inhibit
function
Prior art date
Application number
MA38208A
Other languages
English (en)
Inventor
Chang-Sun Lee
Ramil Baiazitov
Liangxian Cao
Thomas Davis
Wu Du
Ronggang Liu
Young-Choon Moon
Steven Paget
Hongyu Ren
Nadiya Sydorenko
Richard Wilde
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MA38208B1 publication Critical patent/MA38208B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

L'invention concerne des composés pyrimidines inversés substitués aminés et des formes de ceux-ci qui inhibent la fonction et réduisent le taux d'une protéine de site 1 d'intégration du virus de la leucémie murine de moloney spécifique des lymphocytes b (bmi-1) et leurs procédés d'utilisation pour inhiber la fonction de bmi-1 et réduire le taux de bmi-1 pour traiter un cancer à médiation par bmi-1.
MA38208A 2012-11-21 2013-11-21 Inhibiteurs de bmi-1 pyrimidines inversés substitués MA38208B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
PCT/US2013/071132 WO2014081906A2 (fr) 2012-11-21 2013-11-21 Inhibiteurs de bmi-1 pyrimidines inversés substitués

Publications (1)

Publication Number Publication Date
MA38208B1 true MA38208B1 (fr) 2021-12-31

Family

ID=50776672

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38208A MA38208B1 (fr) 2012-11-21 2013-11-21 Inhibiteurs de bmi-1 pyrimidines inversés substitués

Country Status (32)

Country Link
US (3) US10428050B2 (fr)
EP (1) EP2922828B1 (fr)
JP (3) JP6412503B2 (fr)
KR (4) KR102455889B1 (fr)
CN (2) CN111423417B (fr)
AR (1) AR093579A1 (fr)
AU (1) AU2013348009C1 (fr)
BR (1) BR112015011760B1 (fr)
CA (1) CA2892045C (fr)
CL (1) CL2015001377A1 (fr)
CR (1) CR20150294A (fr)
CU (1) CU24387B1 (fr)
DK (1) DK2922828T3 (fr)
EA (2) EA031405B1 (fr)
EC (1) ECSP15019948A (fr)
ES (1) ES2821529T3 (fr)
HK (1) HK1215032A1 (fr)
IL (2) IL238871B (fr)
MA (1) MA38208B1 (fr)
MX (2) MX2015006469A (fr)
NI (1) NI201500072A (fr)
NZ (2) NZ708909A (fr)
PE (1) PE20151413A1 (fr)
PH (1) PH12015501130A1 (fr)
PL (1) PL2922828T3 (fr)
PT (1) PT2922828T (fr)
SA (1) SA517381847B1 (fr)
SG (2) SG10201600149VA (fr)
TW (1) TWI623531B (fr)
UA (1) UA118094C2 (fr)
WO (1) WO2014081906A2 (fr)
ZA (1) ZA201503642B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
WO2015003355A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN105593215B (zh) * 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
EP3039015B1 (fr) 2013-08-30 2019-10-30 PTC Therapeutics, Inc. Inhibiteurs de bmi-1 à base de pyrimidines substituées
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
WO2017027709A1 (fr) 2015-08-11 2017-02-16 Cognoa, Inc. Procédés et appareil de détermination d'une évolution du développement grâce à l'intelligence artificielle et à une entrée d'un utilisateur
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
CN108602775B (zh) * 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
EP3580700A4 (fr) * 2017-02-09 2020-11-18 Cognoa, Inc. Plate-forme et système de médecine personnalisée numérique
WO2019028171A1 (fr) 2017-08-01 2019-02-07 Ptc Therapeutics, Inc. Inhibiteur de dhodh pour utilisation dans le traitement de cancers hématologiques
EP3564235A1 (fr) * 2018-05-03 2019-11-06 Northwestern University Dérivés n-hétérocycliques aromatiques en tant qu'inhibiteurs de kinase de protéine kinase activée par mitogène interagissant sur la kinase 1 (mnk1) et 2 (mnk2)
BR112021002630A2 (pt) * 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
EP3911418A1 (fr) * 2019-01-15 2021-11-24 PTC Therapeutics, Inc. Méthode de traitement d'une leucémie aiguë myéloïde
EP3931196A4 (fr) * 2019-02-28 2022-12-14 PTC Therapeutics, Inc. Procédé de traitement d'un myélome multiple
JP2022524424A (ja) 2019-03-11 2022-05-02 ピーティーシー セラピューティクス， インコーポレイテッド 向上したバイオアベイラビリティを有する化合物形態及びその製剤
KR102643554B1 (ko) 2019-03-22 2024-03-04 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
EA202192349A1 (ru) * 2019-03-27 2022-02-01 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Комбинации, пригодные в способе лечения саркомы
BR112021019508A2 (pt) * 2019-04-02 2022-02-01 Hinova Pharmaceuticals Inc Composto de amina aromática e uso do mesmo na preparação de reguladores e inibidores duplos de ar e brd4

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (fr) * 1973-09-20 1977-11-30 Delalande Sa
CA2197298C (fr) 1994-08-13 1999-10-19 Jong Wook Lee Nouveaux derives de la pyrimidine; methodes de preparation
IN188411B (fr) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
JP2003523942A (ja) 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
ES2254238T3 (es) 1999-10-27 2006-06-16 Novartis Ag Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico.
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
JP4105948B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
WO2002024681A2 (fr) 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1351691A4 (fr) * 2000-12-12 2005-06-22 Cytovia Inc 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee
DE60112330T2 (de) 2000-12-15 2006-04-13 Glaxo Group Ltd., Greenford Pyrazolopyridinderivate
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ATE416175T1 (de) 2001-02-20 2008-12-15 Astrazeneca Ab 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
EP1364212B1 (fr) 2001-03-02 2011-02-02 GPC Biotech AG Systeme de dosage a trois hybrides
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
ES2271283T3 (es) 2001-07-03 2007-04-16 Vertex Pharmaceuticals Incorporated Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck.
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003212634A1 (en) 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
WO2003099811A1 (fr) 2002-05-23 2003-12-04 Cytopia Pty Ltd Inhibiteurs de la kinase
ATE447560T1 (de) 2002-06-28 2009-11-15 Nippon Shinyaku Co Ltd Amidderivat
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (fr) * 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Nouveau reactifs de marquage au fluor et de piegeage et procedes de synthese et d'utilisation correspondants
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
JP2006504755A (ja) 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
CN100465173C (zh) 2004-01-12 2009-03-04 西托匹亚研究有限公司 选择性激酶抑制剂
WO2005076854A2 (fr) 2004-02-04 2005-08-25 Smithkline Beecham Corporation Nouveaux composes chimiques
EP2332940B1 (fr) 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles utiles comme inhibiteurs de janus kinases et d'autres proteines kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
EP1854793A4 (fr) 2005-02-28 2011-01-26 Japan Tobacco Inc NOUVEAU COMPOSÉ AMINOPYRIDINE AYANT UNE ACTIVITÉ D'INHIBITION DE LA Syk
EP1858882A1 (fr) 2005-03-10 2007-11-28 Bayer Pharmaceuticals Corporation Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
JP2009541268A (ja) 2006-06-22 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
AU2007304195A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
MX2009004019A (es) 2006-10-19 2009-06-19 Signal Pharm Llc Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa.
JP2010514689A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
PE20081636A1 (es) 2007-01-26 2009-01-10 Smithkline Beecham Corp Inhibidores de antranilamida para aurora quinasa
EP2121633A2 (fr) 2007-02-12 2009-11-25 Merck & Co., Inc. Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées
UY31048A1 (es) 2007-04-25 2008-11-28 Astrazeneca Ab Nuevos compuestos de pirimidina y usos de los mismos
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2203436A1 (fr) 2007-09-17 2010-07-07 Neurosearch A/S Dérivés de pyrazine et leur utilisation en tant que modulateurs des canaux potassiques
MY152948A (en) 2007-11-16 2014-12-15 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
ES2374480T3 (es) 2007-12-07 2012-02-17 Novartis Ag Derivados pirazol y uso de los mismos como inhibidores de quinasas dependientes de ciclina.
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
WO2010002985A1 (fr) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Modulateurs de l’expression de la protéine bmi-1
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
CN102177154A (zh) * 2008-09-02 2011-09-07 神经研究公司 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用
WO2010061903A1 (fr) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Dérivé de pyrimidine et dérivé de pyridine présentant tous deux une activité inhibitrice de pi3k
WO2010092962A1 (fr) 2009-02-12 2010-08-19 アステラス製薬株式会社 Dérivé d'hétérocycle
EP2411387B1 (fr) 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl et 1,3,5-triazinyl benzimidazole sulfonamides et leur utilisation en thérapie anticancéreuse
CN102459265A (zh) 2009-05-27 2012-05-16 雅培制药有限公司 激酶活性的嘧啶抑制剂
WO2010144416A1 (fr) 2009-06-08 2010-12-16 Gaeta Federico C A Composés de pyrazolo[1,5‑a]pyridine substitués à activité multiciblée
ES2604667T3 (es) 2009-06-17 2017-03-08 Vertex Pharmaceuticals Incorporated Inhibidores de la replicación de virus de influenza
EP2451802A1 (fr) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl et 1,3,5-triazinyl benzimidazoles et leur utilisation dans le traitement du cancer
MX2012000711A (es) 2009-07-15 2012-03-16 Abbott Lab Inhibidores de pirrolopirazina de cinasas.
CA2767089A1 (fr) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridines inhibiteurs de kinases
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
JP5734313B2 (ja) 2010-01-12 2015-06-17 アーべー・シオンス チアゾールおよびオキサゾールキナーゼ阻害剤
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
RU2562111C2 (ru) * 2010-08-19 2015-09-10 Ф.Хоффманн-Ля Рош Аг Конверсия соматических клеток в индуцированные репрограмированные нейрональные стволовые клетки (ирнск)
BR112013005889A2 (pt) 2010-09-13 2020-08-25 Novartis Ag triazinaoxadiazóis, composição farmacêutica que os compreende e uso dos mesmos
WO2012050884A2 (fr) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Glycosides cardiaques qui sont de puissants inhibiteurs de l'expression du gène de l'interféron bêta
CA2819373A1 (fr) 2010-12-09 2012-06-14 Amgen Inc. Composes bicycliques en tant qu'inhibiteurs de pim
EP2678332B1 (fr) 2011-02-25 2016-05-18 Yuhan Corporation Dérivés de diaminopyrimidine et leurs procédés de préparation
JP6116554B2 (ja) 2011-07-07 2017-04-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がんの処置のための置換されたアザ複素環
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux

Also Published As

Publication number Publication date
IL265253A (en) 2019-05-30
IL238871B (en) 2019-03-31
NZ746607A (en) 2019-11-29
JP2016504290A (ja) 2016-02-12
KR20220143164A (ko) 2022-10-24
MX2015006469A (es) 2015-10-29
SG11201503982XA (en) 2015-06-29
EP2922828A2 (fr) 2015-09-30
SG10201600149VA (en) 2016-02-26
PT2922828T (pt) 2020-10-12
ECSP15019948A (es) 2016-01-29
NZ708909A (en) 2019-11-29
US20150315182A1 (en) 2015-11-05
ZA201503642B (en) 2020-10-28
AU2013348009A1 (en) 2015-06-04
US11180483B2 (en) 2021-11-23
KR102356487B1 (ko) 2022-02-08
KR20210088740A (ko) 2021-07-14
IL238871A0 (en) 2015-07-30
JP6617186B2 (ja) 2019-12-11
CN111423417B (zh) 2022-11-15
BR112015011760A2 (pt) 2017-07-11
PE20151413A1 (es) 2015-10-23
EP2922828A4 (fr) 2016-07-27
PH12015501130A1 (en) 2015-08-03
BR112015011760B1 (pt) 2022-12-06
AU2013348009C1 (en) 2019-08-08
KR102455889B1 (ko) 2022-10-17
JP6918898B2 (ja) 2021-08-11
US20220064150A1 (en) 2022-03-03
CA2892045A1 (fr) 2014-05-30
CU24387B1 (es) 2019-03-04
AU2013348009B2 (en) 2018-05-17
TWI623531B (zh) 2018-05-11
EP2922828B1 (fr) 2020-07-08
WO2014081906A3 (fr) 2014-07-17
AR093579A1 (es) 2015-06-10
EA201590992A1 (ru) 2015-11-30
WO2014081906A2 (fr) 2014-05-30
UA118094C2 (uk) 2018-11-26
ES2821529T3 (es) 2021-04-26
HK1215032A1 (zh) 2016-08-12
US10428050B2 (en) 2019-10-01
KR20220016305A (ko) 2022-02-08
JP2019031509A (ja) 2019-02-28
CR20150294A (es) 2015-08-20
PL2922828T3 (pl) 2020-12-28
CN104918919A (zh) 2015-09-16
US20200024260A1 (en) 2020-01-23
CN111423417A (zh) 2020-07-17
CA2892045C (fr) 2022-05-31
CU20150053A7 (es) 2015-11-27
DK2922828T3 (da) 2020-08-31
EA031405B1 (ru) 2018-12-28
EA201890142A1 (ru) 2018-06-29
MX2021009892A (es) 2021-09-14
NI201500072A (es) 2016-01-18
CL2015001377A1 (es) 2016-02-19
SA517381847B1 (ar) 2021-07-17
KR20150086345A (ko) 2015-07-27
EA035349B1 (ru) 2020-05-29
TW201427972A (zh) 2014-07-16
KR102275676B1 (ko) 2021-07-12
JP2020055815A (ja) 2020-04-09
JP6412503B2 (ja) 2018-10-24

Similar Documents

Publication Publication Date Title
MA38208B1 (fr) Inhibiteurs de bmi-1 pyrimidines inversés substitués
MA48772B1 (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
EA201690502A1 (ru) Замещенные пиримидиновые ингибиторы bmi-1
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
MA50949B1 (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
AR114687A1 (es) Pares citoquinas / receptores ortogonales biológicamente relevantes
PH12018501268A1 (en) Compounds useful as kinase inhibitors
MA47107B1 (fr) Dérivés de benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine et pyrido[2,3-d]pyrimidine en tant qu'inhibiteurs de kras g12c pour le traitement de cancer du poumon, du pancréas ou de l'intestin
MA43603A1 (fr) Récepteurs chimériques et leurs procédés d'utilisation
EA201792214A1 (ru) Соединения замещенного хиназолина
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
EA201692370A1 (ru) КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
MA39092A1 (fr) Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
MX2021007538A (es) Derivados biciclicos.
MX2021007540A (es) Derivados biciclicos.
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
MA47221A1 (fr) Anticorps monoclonal à pd-l1
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MA41203B1 (fr) Procédés pour la préparation d'un composé diaryl-thiohydantoïne
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA33555B1 (fr) Procédés et compositions pour traiter la leucémie
EA202091253A1 (ru) Схема приема кладрибина для лечения прогрессирующих форм рассеянного склероза
MA40303A1 (fr) Peptides macrocycliques utiles comme immunomoldulateurs